Chapter 4
The recovery facility is quieter than the burn unit.
That’s the first thing I notice — the absence of the constant, low-grade chaos that comes with acute care.
No code calls, no urgent footsteps, no beeping monitors announcing someone else’s crisis.
My room has a window that looks out onto a courtyard with a garden that someone tends with genuine attention — boxwood hedges, late-season mums, a Japanese maple going red at the edges.
I spend the first morning looking at it.
Real color after two weeks of fluorescent white.
The grafts went well. Dr. Sengupta says this like a woman delivering a quarterly earnings report — factual, mildly pleased, already looking at the next objective.
The donor site on my thigh is bandaged and sore, a new pain layered on top of the old one, but she explains that this is expected and temporary.
The grafted areas on my shoulder and upper arm are covered in a compression dressing that I’m not allowed to touch, which is its own particular form of torture for a woman who has built a career on examining things.
“Two weeks before we can assess the take,” she says, checking the edges of the dressing with gloved fingers. “Then we’ll know how much of the graft has integrated and how much needs revision.”
“What’s the expected take rate?”
“For split-thickness autografts in this area, eighty-five to ninety-five percent on the first pass.”
“And if it’s below eighty-five?”
“Then we re-graft the areas that didn’t take.” She looks at me over the top of her surgical mask. “But I’m not expecting that. Your wound bed was clean. The vascularity is good. I think this one is going to be straightforward.”
Straightforward. I add this to my collection of words that have been used by medical professionals to describe my situation: prognosis, recovery, range of motion, graft take, rehabilitation.
Clean words. Clinical words. Words that mean something specific and measurable, and I hold them like handrails in a dark corridor.
They tell me where I am and how far I have to go, and they never once mention my husband.
Physical therapy begins on the third day. My therapist is a woman named Jess who has forearms like she climbs mountains on weekends and a voice that manages to be encouraging without being condescending, which I appreciate more than she probably knows.
“The goal right now is range,” she says, positioning my left arm on a foam wedge. “We’re not pushing for strength yet. Just getting the joint used to movement again.”
“How far can I go?”
“Today? About here.” She lifts my arm to forty-five degrees.
The skin pulls. It doesn’t exactly hurt — the nerves in the grafted area are still reconnecting, so the sensation is strange rather than painful, a tightness that feels like wearing a sleeve two sizes too small.
“That’s your ceiling for now. We’ll add five degrees every session. ”
“How many sessions until full range?”
Jess gives me a look that says she’s heard this question before, usually from patients who think recovery is a problem set with a clean answer. “Depends on the person. The graft. How the scar tissue forms. Some people get to ninety percent in three months. Some people take a year.”
“Give me a number.”
“Sixty sessions to know where you’ll plateau. Two sessions a day, five days a week. So about six weeks of daily work before I can tell you what your arm is going to do long-term.”
Six weeks. I file the number away. Sixty sessions, five degrees at a time, two hundred and seventy degrees of potential arc between where I am and where I was. The math is clean even if the body isn’t. I can do math.
The first session is fifteen minutes. By the end my arm is shaking and I’m sweating through my hospital gown and the tightness has become something closer to burning, which is a word I no longer use casually.
Jess lowers my arm back to the wedge and I lie there breathing and thinking about the article I published last year on dose-escalation protocols in oncology trials — how we push just past the point of tolerability, back off, push again, calibrating the damage against the benefit until we find the edge.
I am my own trial now. Subject and researcher. The conflict of interest is obvious.
By the second week, I’m at sixty degrees.
By the third, seventy-five. I chart my progress the way I chart trial data — a simple line graph, plotted on graph paper Auden brings me from the department supply closet, because I don’t trust myself with a spreadsheet yet.
One-handed typing is slow enough without adding data entry.
Each session gets a point. The line climbs unevenly, with plateaus and small reversals and the occasional jump that Jess attributes to the graft settling and I attribute to stubbornness.
“You’re ahead of schedule,” Jess tells me at the start of week four, flexing my shoulder through a passive stretch that makes my teeth clench. “Most patients don’t hit seventy-five until week six.”
“I’m motivated.”
“I can see that. Just don’t confuse motivated with invincible. Push too hard and the scar tissue contracts instead of stretching. Then we lose ground.”
“I know the dose-response curve,” I say, and she gives me a look that is half amusement, half warning, and fully the look of a woman who has watched too many overachievers injure themselves proving they can.
I ease off. Slightly. I let Jess set the pace instead of negotiating for one more degree, one more repetition.
She is the expert in bodies. I am the expert in data.
Between the two of us, my arm moves a little further each day, and the graph on the paper climbs, and the compression sleeve gets slightly less suffocating, and I start to believe that the seventy-to-eighty-percent number Dr. Sengupta gave me might land on the high end.
The fire investigator’s report arrives on a Tuesday, forwarded by Helen Zhao. I read it at the small desk by the window, the courtyard’s Japanese maple bleeding crimson through the glass.
Cause of fire: electrical fault. Specifically: degraded knob-and-tube wiring in the second-floor walls, original to the house’s 1920s construction, never updated during any of the renovations.
The report notes that the wiring was not up to code and had not been inspected in at least fifteen years.
It further notes that the homeowner’s insurance policy had been renewed annually without an updated inspection, and that the property management company employed by the homeowner had no record of flagging the wiring condition.
I read the report twice. Three times. I am looking for the word negligence and I don’t find it, because fire investigators deal in causes, not culpability. The cause is degraded wiring. The culpability is more complicated.
Langston bought the Hamptons house eleven years ago, before me, before our marriage, back when it was just him and five-year-old Rowena and the beginning of the money that would become Merrifield Biopharma.
He renovated the kitchen. He updated the bathrooms. He built the deck where we had dinner the night of the fire, the one where Rowena asked about my grant and Langston extrapolated my methodology section.
He made the house beautiful and comfortable and his, and he never once looked inside the walls.
The wiring ran behind the plaster for ninety years without incident, and then it didn’t.
Not negligence legally. Not even negligence practically — plenty of old houses have old wiring, and plenty of them don’t burn down.
But the detail sharpens something I’ve been carrying since the fire, a sense that the catastrophe wasn’t an accident in the purest meaning of the word.
It was a thing that could have been prevented by attention.
By someone looking at the bones of the house instead of the surfaces.
By someone asking: what is this structure built on, and is it still sound?
I fold the report and put it in the drawer beside my graph paper. The maple drops another leaf. I watch it fall, and I think about all the things that work until they don’t, all the structures that hold until they fail, all the wiring that runs behind the walls of a life you think is solid.
Auden comes every day. She doesn’t have to — the recovery facility is forty minutes from campus, and she has a full teaching load this semester and a paper under review at the Journal of Clinical Trial Design — but she comes anyway.
She brings coffee and departmental gossip and the particular kind of companionship that doesn’t require me to perform being okay.
“Jansen asked about you at the faculty meeting,” she says, cross-legged in the visitor chair with her own coffee. “He wants to know if you’ll be back for the spring symposium.”
“When is it?”
“March.”
March. Five months from now. The book span of my recovery, laid out in academic deadlines. “Tell him maybe.”
“I told him you were recovering from a fire and that the answer was ‘we’ll see,’ and he said, ‘Of course, of course,’ and then asked if you could send your panel notes anyway.”
“Classic Jansen.”
“I told him to email you directly. Figured you could use something to ignore.”
I almost smile. The departmental politics of Boston University’s biostatistics program have always been a reliable source of low-stakes entertainment — the committee feuds, the grant-application backstabbing, the annual debate about whether to merge the computational track with the applied track.
Auden feeds me these stories like a nurse feeding morphine: measured doses of normal life, administered at intervals, enough to take the edge off without letting me forget where I am.